Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5031109 | 0.89 | LMNA (0.33) | ALDH1A1GAALMNA | |
| SCHEMBL1053239 | 0.80 | — | — | |
| SCHEMBL3980701 | 0.78 | — | — | |
| SCHEMBL9806307 | 0.74 | — | — | |
| SCHEMBL728353 | 0.74 | — | — | |
| SCHEMBL24432934 | 0.72 | ALDH1A1 (0.35) | ALDH1A1GAAKDM4ERXFP1 | |
| SCHEMBL10877314 | 0.72 | ALDH1A1 (0.35) | ALDH1A1GAAKDM4ERXFP1 | |
| SCHEMBL11724746 | 0.72 | ALDH1A1 (0.35) | ALDH1A1GAAKDM4ERXFP1 | |
| SCHEMBL6162148 | 0.72 | ALDH1A1 (0.35) | ALDH1A1GAAKDM4ERXFP1 | |
| SCHEMBL10877299 | 0.72 | ALDH1A1 (0.35) | ALDH1A1GAAKDM4ERXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065349-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | BUCHWALD STEPHEN L (US) | 2005-03-24 | — | — | US | disclosed |
| US-6787655-B2 | TRANSITION-METAL-CATALYZED ASYMMETRIC 1,4-ADDITION OF A NUCLEOPHILE, E.G., HYDRIDE, TO CYCLIC AND ACYCLIC ENOATES AND ENONES AND THE CATALYST CONTAINING A COPPER AND AN ASYMMETRIC BIDENTATE BISPHOSPHINE LIGAND | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2004-09-07 | — | — | US | disclosed |
| US-20030125563-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-03 | — | — | US | disclosed |
| US-6465664-B1 | CATALYZED WITH A TRANSITION METAL CATALYST COMPOSED OF A COPPER COMPOUND AND AN ASYMMETRIC LIGAND, SUCH AS A PHOSPHINE, A NUCLEOPHILE AND A BASE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2002-10-15 | — | — | US | disclosed |
| WO-2001019761-A2 | ASYMMETRIC 1,4-REDUCTIONS OF AND 1,4-ADDITIONS TO ENOATES AND RELATED SYSTEMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065349-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | APEX1, AP2A1, ENPP1 | ALDH1A1 123/4885GAA 1975/4885HPGD 1367/4885 |
| US-20030125563-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | APEX1, AP2A1, ENPP1 | ALDH1A1 123/4885GAA 1975/4885HPGD 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.